Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

出版年份 2017 全文链接

标题

作者

关键词

Melanoma, Programmed cell death-1, PD-L1, Ipilimumab-refractory, Survival

出版物

Volume 86, Issue -, Pages 37-45

出版商

Elsevier BV

发表日期

2017-11-09

DOI

10.1016/j.ejca.2017.07.022

联系作者

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discuss science. Find collaborators. Network.

Join a conversation